Home » Stocks » ARCT

Arcturus Therapeutics Holdings Inc. (ARCT)

Stock Price: $40.33 USD 0.81 (2.05%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $38.72 -1.61 (-3.99%) Apr 16, 7:14 PM
Market Cap 1.06B
Revenue (ttm) 9.54M
Net Income (ttm) -72.15M
Shares Out 26.28M
EPS (ttm) -3.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $40.33
Previous Close $39.52
Change ($) 0.81
Change (%) 2.05%
Day's Open 39.75
Day's Range 38.53 - 40.41
Day's Volume 515,369
52-Week Range 17.32 - 129.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrials--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

2 weeks ago - Business Wire

Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 64.47% over the past year to ($1.25), whi...

1 month ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

1 month ago - Business Wire

Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021

1 month ago - Business Wire

With the trading day more than halfway over, the broad markets were trading mixed.

Other stocks mentioned: CHKAQ
2 months ago - 24/7 Wall Street

Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.

2 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BioCEO--Arcturus Therapeutics to Present at Upcoming Investor Conferences

2 months ago - Business Wire

Stocks without sturdy fundamentals are toxic for your portfolio. Identifying such bloated stocks accurately and dumping them at the right time can protect your returns.

Other stocks mentioned: ARMK, HXL, TAL
2 months ago - Zacks Investment Research

Probably not, if you're investing for the long term.

Other stocks mentioned: INO, VXRT
2 months ago - The Motley Fool

Investors need to pay close attention to Arcturus Therapeutics (ARCT) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

ARCT peaked and then slumped in recent weeks as investors lost interest in its coronavirus vaccine. Promising platform and advantages suggests this is a worthwhile holding.

2 months ago - Seeking Alpha

With the trading day about half over, the broad markets were pushing higher on Tuesday The S&P 500 and Dow Jones industrial average were both up fractionally, and the Nasdaq posted the largest gain, clo...

Other stocks mentioned: MCD, QCOM, SBUX, TSLA, BIDU, BYND, CHWY ...
2 months ago - 24/7 Wall Street

Only if its COVID-19 vaccine proves to be at least as effective than those developed by its rivals.

3 months ago - The Motley Fool

One Wall Street analyst is very bullish about the biotech's prospects.

3 months ago - The Motley Fool

Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicines company ...

Other stocks mentioned: TDOC, VIVO
3 months ago - Benzinga

Over halfway through the trading day on Thursday, and the broad markets are making a run into the afternoon.

Other stocks mentioned: FDX, LMT, ROKU, ACI, BIG, CME, DDD ...
3 months ago - 24/7 Wall Street

The biotech's shares jumped by 299% last year, propelled by optimism about its COVID-19 vaccine candidate.

3 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #BiotechShowcase--Arcturus Therapeutics to Present at Upcoming Investor Conference

3 months ago - Business Wire

Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.

3 months ago - Zacks Investment Research

This clinical-stage biotech has been a wild ride for investors, and the shifting outlook for its COVID-19 vaccine candidate is the reason why.

3 months ago - The Motley Fool

Shares of Arcturus Therapeutics Holdings Inc. gained 3.7% in premarket trading on Monday after the company said the Food and Drug Administration will allow it to move forward with a Phase 2 clinical tri...

3 months ago - Market Watch

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

3 months ago - Business Wire

Arcturus (ARCT) has selected ARCT-032 as a development candidate for Cystic Fibrosis.

3 months ago - Zacks Investment Research

Investors in fast-moving biotechs made out like bandits.

Other stocks mentioned: CODX, FLGT, INO, MRNA
3 months ago - The Motley Fool

Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.

3 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #CFTR--Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

3 months ago - Business Wire

Two top performers fell back to earth on Tuesday.

Other stocks mentioned: BLNK
3 months ago - The Motley Fool

Investors obviously considered these to be underwhelming, however.

3 months ago - The Motley Fool

Arcturus Therapeutics fell as much as 53% to $40 on Tuesday, extending its losses for a second straight day after Wall Street was disappointed with the medical company's COVID-19 vaccine updates. Arctur...

3 months ago - Business Insider

The biotech announced disappointing early stage results for its single-dose COVID-19 vaccine candidate.

3 months ago - The Motley Fool

An update on its COVID-19 vaccine candidate sent Arcturus Therapeutics Holdings Inc.

3 months ago - 24/7 Wall Street

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares were retreating sharply Tuesday after the company issued an update on its coronavirus vaccine program. What Happened: San Diego, California-based...

3 months ago - Benzinga

Investors respond to results from a Phase 1/2 trial of its COVID-19 vaccine candidate that one analyst said were disappointing.

3 months ago - Market Watch

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Received Approval from Singapore HSA to Proceed with Phase 2 Study of its Vaccine Candidate & Provides New/Updated Clinical/Preclinical Data

3 months ago - Business Wire

One's a healthcare giant. The other is a small clinical-stage biotech.

Other stocks mentioned: JNJ
3 months ago - The Motley Fool

An analyst downgraded the biotech stock.

3 months ago - The Motley Fool

Nothing compares to these companies.

Other stocks mentioned: JNJ, NVAX
3 months ago - The Motley Fool

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

Other stocks mentioned: CVAC, NVAX, VXRT
4 months ago - Zacks Investment Research

They each have a key competitive edge that could set them apart.

Other stocks mentioned: NVAX, VXRT
4 months ago - The Motley Fool

The first to market won't necessarily dominate the market over the long run.

Other stocks mentioned: PFE
4 months ago - The Motley Fool

Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.

Other stocks mentioned: BNTX, JNJ, MRNA, NVAX, PFE, VXRT
4 months ago - The Motley Fool

There's something for every kind of investor with this list.

Other stocks mentioned: NVAX, PFE
4 months ago - The Motley Fool

A biotech that no one has heard of has been making a few investors rich for much of 2020.

4 months ago - The Motley Fool

This could be the perfect time for aggressive investors to scoop up shares.

4 months ago - The Motley Fool

This can happen when a company holds out its hand for a big chunk of fresh capital.

Other stocks mentioned: IBIO, MRNS
4 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Pricing of $150.15 Million Public Offering of Common Stock

4 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease v...

4 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #Clinicaltrial--Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

4 months ago - Business Wire

Don't be surprised if this small biotech takes off in 2021.

4 months ago - The Motley Fool

About ARCT

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issue... [Read more...]

Industry
Biotechnology
Founded
2013
Stock Exchange
NASDAQ
Ticker Symbol
ARCT
Full Company Profile

Financial Performance

In 2020, ARCT's revenue was $9.54 million, a decrease of -54.12% compared to the previous year's $20.79 million. Losses were -$72.15 million, 177.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is 86.15, which is an increase of 113.61% from the latest price.

Price Target
$86.15
(113.61% upside)
Analyst Consensus: Buy